Disruption of the proper enzymatic conformation of HUWE1 should be taken into consideration when small molecule inhibitors or peptides are developed as a novel therapeutic intervention in the future, which will fulfill the principal rule of precision medicine based on tumor types, genetic contents, and molecular/cellular presentations. The gene discussed is HUWE1; the disease is neoplasm.